Clinical trial NCT00614302: Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Population
Official title: Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Patient Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HIV Infections
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2008-02-13
Enrollment: 428
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: HIV patients

Brief summary: Data collection for better patient characterization in a highly treatment experienced population. Studying the clinical practice for the treatment of HIV multiexperienced patients in the real life.

The research will be divided into two phases:

* The first phase intends to define and understand the clinical practice using a questionnaire about general topics: definitions of multiexperienced patients and VL failure, therapeutic strategies and behaviour in particular cases.
* The second part of the research will collect the clinical data of double PIs failure patients.


Eligibility criteria: Inclusion Criteria:

Patients double PIs failure

Exclusion Criteria:

Not Applicable

Primary outcomes:
measure: To study in the clinical practice the choice of a specific salvage regimen for multiexperienced patients.
timeFrame: 48 weeks
Secondary outcomes:
measure: Reason of each VL failure or switching
timeFrame: 48 weeks
Other outcomes:
Locations:
city: Ancona
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Bari
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Benevento
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Bisceglie
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Bologna
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Brescia
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Busto
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Caserta
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Catania
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Cremona
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Firenze
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Genova
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Legnano
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Milano
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Napoli
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Padova
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Palermo
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Pavia
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Roma
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Sassari
country: Italy
facility: Boehringer Ingelheim Investigational Site
city: Torino
country: Italy
facility: Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References: